Prince William announces 15 Finalists for inaugural year of the £50 million Earthshot Prize
17.9.2021 20:01:00 EEST | Business Wire | Press release
The Earthshot Prize announces today its first-ever shortlist of 15 Finalists, each with a chance of winning £1million to support their innovative environmental solutions to the greatest challenges facing the planet.
Prince William said: "Over half a century ago, President Kennedy’s ‘Moonshot’ programme united millions of people around the goal of reaching the moon. Inspired by this, The Earthshot Prize aims to mobilise collective action around our unique ability to innovate, problem solve and repair our planet.
“I am honoured to introduce the 15 innovators, leaders, and visionaries who are the first ever Finalists for The Earthshot Prize. They are working with the urgency required in this decisive decade for life on Earth and will inspire all of us with their optimism in our ability to rise to the greatest challenges in human history.”
Launched by Prince William and The Royal Foundation in October 2020, The Earthshot Prize is the most prestigious global environment prize in history. Like President John F. Kennedy’s ‘Moonshot’ did almost 60 years ago, the Prize aims to unleash an unprecedented wave of innovation and leadership to tackle our greatest environmental challenges. The Earthshot Prize will be awarded every year for the next decade, discovering a total of 50 Winners.
Five of these 15 Finalists will be awarded The Earthshot Prize and will win £1million in Prize funding for the best solutions of the five Earthshot goals: Protect and Restore Nature; Clean our Air; Revive our Oceans; Build a Waste-free World; and Fix our Climate. The Winners will be announced during an awards ceremony on 17th October from London’s Alexandra Palace, broadcast in the UK on BBC One and globally on Discovery+.
The Earthshot Prize Finalists for 2021 are:
Protect and Restore Nature:
- Pole Pole Foundation, Democratic Republic of Congo
An inspiring community-led model of conservation that protects gorillas and local livelihoods.
- The Republic of Costa Rica
A pioneering scheme paying local citizens to restore natural ecosystems that has led to a revival of the rainforest.
- Restor, Switzerland
A ground-breaking online platform connecting and empowering local conservation projects.
Clean our Air:
- The Blue Map App, China
China’s first public environmental database enabling citizens to hold polluters to account.
- Takachar, India
A pioneering technology to create profitable products from agricultural waste and put a stop to the burning of crops.
- Vinisha Umashankar, India
A 14-year-old innovator and activist who has designed a solar-powered ironing cart with the potential to improve air quality across India.
Revive our Oceans:
- Coral Vita, Bahamas
A truly cutting-edge breakthrough in coral farming that can restore our world’s dying coral reefs.
- Living Seawalls, Australia
Innovative and replicable seawall panels bringing marine life back to coastal sea defences.
- Pristine Seas, USA
An unprecedented global conservation programme protecting 6.5 million square km of the world’s ocean.
Build a Waste-Free World:
- The City of Milan Food Waste Hubs, Italy
A city-wide initiative that has dramatically cut waste while tackling hunger.
- Sanergy, Kenya
A circular sanitation solution that converts human waste into safe products for local farmers.
- WOTA BOX, Japan
A tiny water treatment plant that turns 98% of wastewater into clean water.
Fix our Climate:
- AEM Electrolyser, Thailand/Germany/Italy
An ingenious green hydrogen technology developed to transform how we power our homes and buildings.
- Reeddi Capsules, Nigeria
Solar-powered energy capsules making electricity affordable and accessible in energy-poor communities.
- SOLbazaar, Bangladesh
The world’s first peer-to-peer energy exchange network in a country on the front-line of climate change.
All 15 Finalists will receive support from The Earthshot Prize Global Alliance Members, an unprecedented network of global businesses, who will help scale their solutions for even greater impact.
Of these 15 Finalists, the five Winners will be selected by The Earthshot Prize Council, a diverse team of influential individuals which includes: HRH Prince William, Her Majesty Queen Rania Al Abdullah of Jordan, Sir David Attenborough, Dr Ngozi Okonjo-Iweala, Indra Nooyi, Shakira Mebarak, Christiana Figueres, Luisa Neubauer, Cate Blanchett, Yao Ming, Daniel Alves Da Silva, Ernest Gibson, Hindou Oumarou Ibrahim, Jack Ma, and Naoko Yamazaki.
In the run-up to the prize-giving ceremony on 17 October, BBC and Discovery will release a 5-part documentary series THE EARTHSHOT PRIZE: REPAIRING OUR PLANET, featuring Earthshot Prize Council Members including Prince William, Shakira Mebarak, Daniel Alves Da Silva and Sir David Attenborough.
For more information about the Finalists and The Earthshot Prize, visit: www.earthshotprize.org, email Claire Straw: TEPmedia@freuds.com, download media pack here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210917005454/en/
Contact information
Claire Straw:
TEPmedia@freuds.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom